The expression of bcl-x protein, a bcl-2-related protein present in cortical thymocytes, activated lymphocytes, and plasma cells of reactive lymph nodes, was investigated in 44 cases of Hodgkin's disease (HD) in parallel with bcl-2 and Epstein-Barr virus (EBV) status. Eighty-six percent of the cases were positive for bel-x, among them 27% with a strong signal in more than 75% of the Reed-Sternberg cells. Positivity for M -x was found in, respectively, 100% and 92% of the nodular sclerosis and mixed cellularity subtypes, although 4 cases of lymphocyte predominance subtype were NE OF THE MOST prominent enigmas concerning Hodgkin's disease (HD) is the origin of its putative malignant cell, ie, the Reed-Stemberg (RS) cell. Almost every cell of the lymphoid system, including macrophages or histiocytes,' dendritic reticulum cells,2 granulocytes,3 or B or T lymphocytes4 has been implicated. More recently, it has been reported that the t(14; 18)(q32;q21) translocation, typical of follicular B-cell lymphoma, could be detected in HD.5-7 The t(14; 18) translocation, which fuses the bcl-2 gene on chromosome band 18q21 to the Ig gene on chromosome band 14q32, is thought to activate bcl-2, a 25-kD protein able to block apoptosis.' The association of the t( 14; 18) translocation with HD has been reported to support the B-cell origin of RS cells.5 Nevertheless, other reports failed to demonstrate frequent t( 14; 18) translocation in HD.9-'4 More recently, the possibility that the t( 14; 18) translocation may be found in cells representing the reactive component of HD has been Therefore, the exact role of bcl-2 in HD remains unclear.
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Of interest, bcl-2 belongs to an expanding family of proteins that regulate cell death. This family includes bax, a homolog able to dimerize with bcl-2 and that promotes apoptosis,17 and bcl-x. bcl-x is a bcl-2-related gene that was recently isolated by genomic and cDNA library screening by hybridization with a bcl-2 probe.18 Human bcl-x can generate two proteins through an alternative splicing mechanism: bcl-x-L (241 amino acids), the longer form of the protein that is a blocker of apoptosis, and bcl-x-S (178 amino acids), the shorter form of the protein that promotes programmed cell death.I8
bcl-x mRNA has been detected in CD4+ CD8+ T cells and in stimulated peripheral blood T cells.'8 Recently, polyclonal antibodies were obtained against synthetic peptides of the human bcl-x proteins that were able to detect both bcl-x-L and bcl-x-S by immunohistochemistry without cross-reacting with b~l -2 . '~ bcl-x immunostaining was observed in numerous cell types, including cortical thymocytes, activated lymphocytes, and plasma cells in reactive human lymph nodes." This prompted us to study the immunodetection of bcl-x in RS cells of 44 lymph nodes from HD patients and to compare it with bcl-2. Furthermore, because Epstein-Barr virus (EBV) is frequently found in HDZ0 and because EBV latent membrane protein 1 (LMP1) has been shown to upregulate the bcl-2 gene in Burkitt's lymphoma cell lines,"
we also performed EBV detection in all cases.
MATERIALS AND METHODS
Study design and patients' projle. Forty-four cases of HD were retrospectively analyzed for immunohistochemistry. The tissues were lymph node biopsy specimens that had been processed routinely, ie, fixed in ethanol-based Bouin's fluid (Duboscq-Brasil) and paraffin-embedded. The distribution of cases according to subtype was as follows: 4 lymphocyte predominance (LP), 14 nodular sclerosis (NS), and 26 mixed cellularity (MC) ( Table 1) .
Immunohistochemistry. bcl-x polyclonal antisera (no. 1695) were raised against peptides corresponding to amino acids 46 to 66 of the human bcl-x protein and have been described in detail elsewhere." bcl-2 monoclonal antibody was a gift from Dr D.Y. Mason (Oxford, UK)." The standard immunophenotype of RS cells was performed on paraffin sections according to Chittal et al.23 Antibodies were shown using the streptavidin-biotin complex StreptABComplexkIRP Duet (DAKO, Glostrup, Denmark; K692) on routinely processed paraffin sections with prior antigen retrieval using microwave heating.z4 Assessment for positivity was described as follow: negative if less than 1% of tumor cells were positive; +, if 1% to 50% tumor cells were positive, ++, if 50% to 75% tumor cells were positive; and +++, if greater than 75% tumor cells were positive.
In situ hybridization. In situ hybridization for EBV detection has been described el~ewhere.'~ Briefly, the DAKO hybridization kit was used, which makes use of a cocktail of EBV small RNA (EBER) oligonucleotides (1 oligonucleotide corresponding to EBERl and 1 corresponding to EBER2, both of 30-base length) labeled with fluorescein isothiocyanate.
RESULTS
bcl-x reactivity was first tested on two reactive lymph nodes as a control. Plasma cells, large cells within interfollicular area (activate lymphocytes presumably), and a few scattered lymphocytes within germinal centers were stained, as previously reported (data not shown)." Among the 44 cases with HD, 38 (86%) were found to be positive for bcl-x (Table I and Fig 3) . Small reactive lymphocytes were positively stained and served as a positive internal control for bcl-2. In general, the intensity of bcl-x staining of RS cells was stronger than bcl-2. In addition, the percentage of RS cells that stained positive for bcl-x was also generally greater than for bcl-2. For example, 12 cases (27%) had more than 75% of RS cells stained for bcl-x, whereas in no case was bcl-2 staining of RS cells found as frequently (Table I) . EBV small RNAs were detected in 19 of 44 (43%) of the cases by in situ hybridization with EBER oligonucleotides. The signal was clearly nuclear in each case and abolished by RNAseA but not by DNAse 1 pretreatment, as previously reported (data not shown).2s
None of the four LP-HD samples were stained by either bcl-x nor bcl-2 antibodies (Table 1 ). In contrast, 14 of 14 (100%) of NS-HD and 24 of 26 (92%) of the MC-HD stained for bcl-x antibodies ( Table 1) . For bcl-2, 11 of 14 (78%) of the NS subtype cases and 9 of 25 (36%) of the MC subtype cases were bcl-2 positive (Table I) . When bcl-x and bcl-2 immunostaining were related to EBV status, 19 of 19 of the EBER-positive samples were positive for bcl-x, whereas only 7 of 18 (38%) of the cases were bcl-2 positive.
DISCUSSION
Although HD is a well-defined clinical entity, its pathogenesis and cellular origin remain an enigma. The RS cells constitute only 1% or less of the total cell population in the tumor, with the remainder consisting primarily of reactive benign cells. The findings that the t( 14; 18) translocation, a genetic event described in follicular B-cell lymphoma,26 was present in HD tissues supported a B-cell origin for HD.' Nevertheless, this result raised a controversy because other groups failed to detect the t( 14; 18) translocation in HD by using the same m e t h~d . " "~ bcl-x, a bcl-2-related protein, has recently been shown to be expressed in human lymph nodes, especially in plasma cells and in some activated lymphocytes." This distribution differs strikingly from bcl-2, which is usually found in the majority of resting long-lived memory lymphocytes located in the mantle zone and in many interfollicular lymphocytes." We have shown in this study that bcl-x is strongly associated with the RS cells of HD in most cases (86%), allowing for the possible use of bcl-x immunostaining as a new tool for RS cell immunohistochemistry.
Immunoblot analysis of bcl-x has been previously performed in a wide variety of normal tissues, demonstrating that in all tissues examined, including in lymph nodes, the bcl-x-L protein was predominantly detected, whereas the bcl-x-S protein was far less frequent." In HD samples, in which the tumor cells are rare, it may be difficult to address this question by either immunoblot or reverse transcriptasepolymerase chain reaction. Furthermore, monoclonal antibodies specific for the two forms of the bcl-x protein are not yet available and may be difficult to obtain, because the bclx-S protein differs from bcl-2 and bcl-x-L in that an internal region of 63 amino acids, which is highly homologous among members of the bcl-2 protein family, has been deleted For personal use only. on October 27, 2017. by guest www.bloodjournal.org From For personal use only. on October 27, 2017. by guest www.bloodjournal.org From by alternative splicing of the primary bcl-x mRNA transcript." Whatever the type of the bcl-x protein present in the RS cells, the finding in the same HD samples of bcl-x and bcl-2 (19 of 44 or 43%) raises the possibility of interaction between these two proteins within RS cells, because Sat0 et a12' recently showed interactions between bcl-2 and the bclx proteins by using a yeast two-hybrid system. Furthermore, another bcl-2 homology, mcl-l, has also been detected in RS cellsz7 and has been shown to be capable of binding to bc1-X-L." Although not examined here, other proteins such as the recently described bad (bcl-2hcl-x-L associated death promoter) might be involved in the regulation of cell death in RS cells, because it has been shown to bind to b~1-x.'~ bcl-x immunodetection was found to be more frequent in EBV-positive cases, with 100% of the tumors being positive. Because EBV LMPl has been reported to upregulate bcl-2 expression in vitro and to protect EBV-infected B cells from programmed cell death," it is tempting to speculate that the bcl-x gene may also be upregulated by the same mechanism. Moreover, open reading frames within the EBV gene BHRFl possess homology to b~l -2 '~ and BHFW overexpression has been reported to block apoptosis. This finding raises the possibility that EBV BHRFl might recognize other members of the bcl-2 family including bcl-x.
In conclusion, we have found that bcl-x gene expression is high in RS cells of HD, especially the NS and MC subtypes and in EBV-positive tumors, suggesting that apoptosis-regulatory proteins may have a role in the pathogenesis of HD.
